
Objective: Natural agents may be useful substitutes for prescription antidepressants. Rhazya stricta possesses antioxidant, anti-inflammatory, and neuroprotective properties. Therefore, this study aimed to evaluate the potential antidepressant effects of Rhazya stricta. Methods: Rhazya stricta was extracted in methanol using maceration. Using the forced swimming test (FST) on C57BL/6 mice and the tail suspension test (TST) on BALB/c mice, antidepressant activity was assessed. The animals were divided into the following groups: methanolic extract of Rhazya stricta (10, 20 and 40 mg/kg; n = 6 per group), standard-treatment groups (citalopram and desipramine; n= 6 per group), and control (saline with 2% DMSO; n=6). Intraperitoneal injections (10 ml/kg of mice) were used. Analysis of variance was used to examine the data, and LSD post hoc tests were then performed. Data are expressed as the mean±standard error of the mean (SEM). Results: Citalopram (10 mg/kg) and desipramine (20 mg/kg), two antidepressant-positive controls, significantly reduced the immobility time in the FST (from 129.5±4.9 to 73.7±2.5and 82.8±5.1 s, respectively) and TST (from 82.5±2.9 to 45.3±1.9 and 46±1.8 s, respectively) compared with the control group (p<0.001). Methanolic extract of Rhazya stricta significantly decreased immobility time in both behavioral models with progressively greater effects at higher doses within the range tested, reaching the largest effect at 40 mg/kg (p<0.001). Conclusion: The methanolic extract of Rhazya stricta demonstrated antidepressant-like activity in the FST and TST in mice, particularly at 40 mg/kg. Further studies are required to identify the active constituents and establish the underlying mechanisms, safety, and pharmacological relevance.
Objective: The ongoing opioid crisis in the United States underscores the need for safer non-opioid analgesics due to the risks of dependence and serious adverse effects. Suzetrigine, a newly approved selective NaV1.8 (Voltage-gated sodium channel 1.8) inhibitor by the U. S. Food and Drug Administration, represents a novel mechanism-based therapy for acute pain. While clinical data are promising, its real-world safety profile remains limited. Therefore, this study utilizes the FDA Adverse Event Reporting System (FAERS) to identify emerging adverse event signals through disproportionality analysis. Methods: A retrospective pharmacovigilance study was conducted using data from the FDA Adverse Event Reporting System to assess adverse events associated with Suzetrigine. Reports from post approval period (January-December 2025) were analyzed, including only cases where the drug was the primary suspect, with duplicates removed. The data were downloaded/extracted in March 2026, at which time the Q4 2025 FAERS file was publicly available on the FDA website. Adverse events with ≥ 30 reports were included for analysis. Disproportionality measures, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), and chi-square test, were applied. A signal was considered significant if ROR>1 with a 95% C I excluding 1, PRR ≥ 2, and χ² ≥ 4. All analyses were conducted using Microsoft Excel to identify and rank potential safety signals. Results: A total of 633 adverse event reports associated with Suzetrigine were identified, of which 64 (10.1%) were serious, including three reported fatalities. Disproportionality analysis using the FDA Adverse Event Reporting System identified six significant safety signals meeting predefined criteria. The strongest signals were paresthesia (ROR 13.72) and muscle spasms (ROR 8.68), suggesting a potential mechanism-related effect linked to NaV1.8 inhibition. Moderate signals included pruritus, dizziness, nausea, and rash, with pruritus being the most frequently reported event (n = 71). Overall, neurological and dermatological events predominated, with paresthesia and muscle spasms emerging as the most prominent signals. Conclusion: Post-marketing FAERS data for Suzetrigine reveal strong neurological signals, notably paresthesia and muscle spasms, and frequent pruritus, consistent with its selective NaV1.8 mechanism. Moderate signals for dizziness, nausea, and rash were also observed. These early findings provide the first real-world safety profile for this novel analgesic, although confirmatory studies are needed.
Objective: Type 2 diabetes mellitus (T2DM) is characterised by progressive β-cell dysfunction and chronic hyperglycaemia. The enzyme Dipeptidyl peptidase-4 (DPP-4) is an important therapeutic target which is involved in the degradation of incretin hormones such as Glucagon-like peptide-1 (GIP) and Glucose-dependent insulin tropic polypeptide (GIP). Despite several DPP-4 inhibitors in use, there are rising concerns regarding their cost, adverse effects and long-term safety. Niazimicin A, a type of thiocarbamate glycoside isolated from Moringaoleifera Lam., has demonstrated pharmacological activities; but its interaction with DPP-4 remains unexplored. This molecular docking study investigated the binding potential of Niazimicin A against DPP-4. Methods: Protein data bank was used to retrieve the three-dimensional structure of DPP-4 (PDB ID: 5Y7H) and was prepared for docking. Niazimicin A (PubChem C ID: 10247749) was optimised and converted into PDBQT format. AutoDock Vina was used for molecular docking with a predefined grid box. Protein–ligand interactions were analysed using discovery studio visualizer and docking validation was performed through re-docking of the co-crystallized ligand. Results: Niazimicin A showed stable docking poses ranging from − 2.816 to −0.090 kcal/mol with a best binding energy of −2.816 kcal/mol. The interaction analysis identified hydrogen bonds with GLN714, SER239, PHE713 and THR706 along with carbon-hydrogen and hydrophobic interactions involving TYR238, TYR241 and PRO249. Docking validation confirmed accurate reproduction of the native ligand binding pose. Conclusion: Niazimicin A exhibited favourable non-covalent interactions within the DPP-4 active site, suggesting its potential as a natural lead compound for antidiabetic drug discovery. Further experimental and pharmacokinetic studies are recommended.
Objective: To formulate and evaluate palbociclib-loaded nanosponges (PB-NSPs) as a controlled drug delivery system to improve the solubility, stability, and release behavior of palbociclib for cancer therapy. Methods: PB-NSPs were prepared using β-cyclodextrin (β-CD) and characterized for particle size, zeta potential, encapsulation efficiency, and morphology. Cytotoxicity was evaluated by MTT assay against MCF-7 and A498 cell lines. In vitro drug release studies were performed to assess the release characteristics of the formulation. Results: The optimized PB-NSPs exhibited a particle size of 149.7±2.6 nm, zeta potential of −23.6±2.16 mV, and encapsulation efficiency of 77.33±2.82%. Cytotoxicity studies demonstrated concentration-dependent reduction in cell viability. Pure palbociclib showed IC₅₀ values of 43.168 µg/ml in MCF-7 cells and 58.11 µg/ml in A498 cells, whereas PB-NSPs showed IC₅₀ values of 54.054 µg/ml and 63.77 µg/ml, respectively. Although PB-NSPs exhibited slightly higher IC₅₀ values than the pure drug in the 48 h assay, the formulation demonstrated sustained drug release and favorable physicochemical properties. Conclusion: PB-NSPs demonstrated desirable physicochemical characteristics and controlled release behavior, indicating their potential as a promising nanosponge-based drug delivery system for prolonged and targeted delivery of palbociclib in cancer therapy.
Objective: This study aimed to perform comprehensive preformulation profiling of beta-sitosterol to establish a foundational database for the design of optimized lipidic carriers. Methods: Characterization involved determining the melting point by the capillary method for purity and crystalline assessment. UV spectroscopy identified maximum absorbance (λmax) for quantification, while FTIR confirmed molecular structure and functional groups. The partition coefficient (log P) was evaluated using the shake-flask method in an n-octanol/water system to assess lipophilicity. Results: The melting point was found to be around 138 °C, indicating high purity. UV analysis showed a lambda max at 210 nm, while FTIR spectra displayed peaks for O-H and C-H stretching, confirming chemical integrity. A high partition coefficient (Log P = 8.1) indicated significant lipophilicity. Conclusion: The preformulation studies successfully characterized beta-sitosterol. Its high lipophilicity and distinct thermal profile confirm its suitability for encapsulation within lipid-based delivery systems, such as solid lipid nanoparticles, nanolipid carriers or liposomes.